A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 381 participants.

Also called NCT05261126

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 381 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05261126
  • jRCT jRCT2031210701
  • EudraCT 2021-005221-24
Main results
  • Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 Journal of the American College of Cardiology, 2023-04-25 DOI, PubMed 36889610

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Japan, Mexico, Norway, South Korea, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05261126. Randomized; double masking; primary purpose treatment. Start 2022-03-10 (actual); primary completion 2022-11-28 (actual). Results posted on 2023-12-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
Condition
Hypercholesterolemia
Intervention (Drug)
Enclitide Chloride
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct05261126
Content hash
2fea1ccc43e35ded95aa6ec2a2e4299e25a659f7e9837a5b317fcfa893f26296